C V Asche

Summary

Affiliation: University of Illinois at Chicago
Country: USA

Publications

  1. ncbi request reprint Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases
    Brian Seal
    Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA
    Appl Health Econ Health Policy 12:547-57. 2014
  2. ncbi request reprint Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus
    Carl V Asche
    Center for Outcomes Research, University of Illinois College of Medicine at Peoria, One Illini Drive, Peoria, IL, 61656 1649, USA
    Pharmacoeconomics 32:15-27. 2014
  3. ncbi request reprint Medical costs associated with use of systemic therapy in adults with colorectal cancer
    Brian S Seal
    U S Health Economics and Outcomes Research, Bayer HealthCare Pharmaceuticals Inc, Wayne, New Jersey, USA
    J Manag Care Pharm 19:461-7. 2013
  4. pmc Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids
    Carl Victor Asche
    Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah, USA
    Int J Chron Obstruct Pulmon Dis 7:201-9. 2012
  5. ncbi request reprint Impact of elevated intact parathyroid hormone on mortality and renal disease progression in patients with chronic kidney disease stages 3 and 4
    C V Asche
    University of Illinois, Peoria, IL 61605, USA
    Curr Med Res Opin 28:1527-36. 2012

Collaborators

  • Sean D Sullivan
  • Shelah Leader
  • Brian Seal
  • Syam Sarma
  • Brian S Seal
  • Michael Eaddy
  • Scott D Ramsey
  • Ken Shermock
  • Erin A Zagadailov
  • Eileen Farrelly
  • Satish Valluri
  • Charlie Kreilick
  • Scott Ramsey
  • Jinma Ren
  • Kenneth M Shermock
  • Susan H Foltz Boklage

Detail Information

Publications5

  1. ncbi request reprint Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases
    Brian Seal
    Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA
    Appl Health Econ Health Policy 12:547-57. 2014
    ..As new treatment patterns emerge, it will be imperative to understand treatment patterns and costs of care prior to the advent of novel treatments...
  2. ncbi request reprint Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus
    Carl V Asche
    Center for Outcomes Research, University of Illinois College of Medicine at Peoria, One Illini Drive, Peoria, IL, 61656 1649, USA
    Pharmacoeconomics 32:15-27. 2014
    ....
  3. ncbi request reprint Medical costs associated with use of systemic therapy in adults with colorectal cancer
    Brian S Seal
    U S Health Economics and Outcomes Research, Bayer HealthCare Pharmaceuticals Inc, Wayne, New Jersey, USA
    J Manag Care Pharm 19:461-7. 2013
    ..New cytotoxic agents and regimens, as well as immunotherapeutics, have recently been introduced for treatment of colorectal cancer (CRC). ..
  4. pmc Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids
    Carl Victor Asche
    Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah, USA
    Int J Chron Obstruct Pulmon Dis 7:201-9. 2012
    ....
  5. ncbi request reprint Impact of elevated intact parathyroid hormone on mortality and renal disease progression in patients with chronic kidney disease stages 3 and 4
    C V Asche
    University of Illinois, Peoria, IL 61605, USA
    Curr Med Res Opin 28:1527-36. 2012
    ..To estimate the impact of elevated intact parathyroid hormone levels on time to death and renal replacement therapy in patients with chronic kidney disease stages 3 and 4...